Overcoming challenges in RNA manufacturing

Since the COVID-19 pandemic, the demand for RNA-based technology has boomed due to its therapeutic potential to fight a range of diseases. As a developing drug modality, innovation challenges still need to be overcome to create more efficient and cost-effective manufacturing approaches. 

CPI’s RNA Centre of Excellence is a UK-based capability able to develop and manufacture lipid nanoparticle-encapsulated messenger and self-amplifying RNA vaccines and therapies ready for use in early-phase clinical trials. We have one of the largest concentrations of experts in RNA technology in the UK. 

Find out what we learned about RNA manufacturing, encapsulation and scale-up as part of the Government’s Vaccine Taskforce and how we work with companies of all sizes to progress their discoveries and optimise their processes. 

In this webinar we will talk about:

1. The challenges to consider when developing manufacturing processes for RNA 
2. The necessary steps that form an mRNA-LNP end-to-end manufacturing process 
3. Our experience of successful manufacturing solutions including platform and ​‘plug and play’ approach. 
4. Considerations for early-stage clinical manufacturing.
5. Q&A